Jasper Therapeutics, Inc. (JSPR)

USD 21.01

(-6.41%)

Market Cap (In USD)

315.17 Million

Revenue (In USD)

-

Net Income (In USD)

-64.46 Million

Avg. Volume

222.57 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
5.0-31.01
PE
-
EPS
-
Beta Value
2.199
ISIN
US4718712023
CUSIP
471871103
CIK
1788028
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Ronald A. Martell
Employee Count
-
Website
https://jaspertherapeutics.com
Ipo Date
2020-01-10
Details
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.